Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions emphasize the trial's importance, referencing its role as a breakthrough (e.g., 'first level 1 evidence of survival benefit') and its influence on modern cancer therapy, with tone and words conveying excitement and recognition of its historic significance in advancing immunotherapy.
Most discussions recognize the significance of the study in demonstrating improved survival with ipilimumab, reflecting general support for its findings.
The posts show high interest, with mentions of the trial's historical importance and its role in advancing immunotherapy, indicating enthusiasm.
Many discussions reference specific trials, survival statistics, and the broader impact on oncology practice, showing deep engagement.
The discussions highlight the transformative effect on melanoma treatment and the broader field of immunotherapy, emphasizing high-impact implications.
#ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of friends 1st au Dr Stephen Hodi @DanaFarber & Sr au @WalterUrba @ChilesResearch https://t.co/ytNvZYEqEh lead to 2018 @NobelPrize @sitcancer @BMS_ImmunOnc_US https://t.co/gjjVlksq6Z
@pashtoonkasi @SyedAAhmad5 @Aiims1742 @CathyEngMD @agrothey @EileenMOReilly @MPishvaian @mkatzmd @DenboJw @DrJashDatta @TsengJennifer @sepideh_gholami @GIcancerDoc @Shrikhande_SV @ShaalanBeg @SWexner @ScienceMagazine But this one opened the doors to IT in solid tumors. When it’s all said and done, it will be all about immunotherapy. https://t.co/1rxKmQGzoj
@SyedAAhmad5 @Aiims1742 @CathyEngMD @agrothey @pashtoonkasi @EileenMOReilly @MPishvaian @mkatzmd @DenboJw @TheNotoriousHPB @DrJashDatta @TsengJennifer @sepideh_gholami @GIcancerDoc @Shrikhande_SV @ShaalanBeg @SWexner https://t.co/CFHsyTX3q5 1st trial to provide level 1 evidence of survival benefit from immunotherapy in melanoma. Although PD1 blockers have been more efficacious, this study of anti-CTLA-4 led to a transformation in the practice of oncology. @WalterUrba @ODayMD @wolchokj
@klmatter This study used the best standard of care approved at the time, Ipilimumab, as the control arm. It had already been proven to improve OS compared with a cancer vaccine. https://t.co/zaMI8PBS4P
@DCSZ14 @StassenFrank @ing_thegame Deze studie heeft een 10 maanden vs 6 maanden survival median. Zoals Frank al stelde; elke maand is er dan 1 extra https://t.co/Hs32aDSevl
@EricTopol @VirusesImmunity @DanaFarber This brings to mind the trial that helped lead to the first approval of #CTLA4, by Hodi et al in @NEJM: https://t.co/yy9r9l7JPf
In this podcast episode, we explore why developing cancer vaccines is so challenging, the differences between prophylactic and therapeutic vaccines, and how mRNA vaccine successes might influence tumor vaccine research…
This video discusses a 2010 study demonstrating how Ipilimumab improves survival in metastatic melanoma patients by targeting CTLA4. It covers the trial design, survival results, mechanism of action, and clinical…
This video explains a 2010 study published in The New England Journal of Medicine that transformed advanced melanoma treatment with Ipilimumab, demonstrating a significant survival benefit and opening new frontiers in…
This video explains a 2010 study demonstrating that Ipilimumab significantly improves survival in metastatic melanoma patients, marking a milestone in immunooncology and highlighting its mechanism, trial design, and…
This video explains a groundbreaking 2010 study demonstrating that Ipilimumab nearly doubles survival in metastatic melanoma patients, marking a major advancement in immuno-oncology and cancer treatment. It covers trial…
This video discusses a 2010 study demonstrating how Ipilimumab significantly improves overall survival in metastatic melanoma patients. It covers study background, trial design, survival outcomes, and the implications…
This video discusses a 2010 study demonstrating that Ipilimumab significantly improves survival in metastatic melanoma patients, marking a breakthrough in immunotherapy. It covers trial design, mechanisms, outcomes, and…
This groundbreaking 2010 NEJM study demonstrates how Ipilimumab, an immune checkpoint inhibitor targeting CTLA4, significantly improves overall survival in metastatic melanoma patients, marking a new era in…
@EricTopol @VirusesImmunity @DanaFarber This brings to mind the trial that helped lead to the first approval of #CTLA4, by Hodi et al in @NEJM: https://t.co/yy9r9l7JPf
@klmatter This study used the best standard of care approved at the time, Ipilimumab, as the control arm. It had already been proven to improve OS compared with a cancer vaccine. https://t.co/zaMI8PBS4P
@DCSZ14 @StassenFrank @ing_thegame Deze studie heeft een 10 maanden vs 6 maanden survival median. Zoals Frank al stelde; elke maand is er dan 1 extra https://t.co/Hs32aDSevl
RT @rbryanbell: @SyedAAhmad5 @Aiims1742 @CathyEngMD @agrothey @pashtoonkasi @EileenMOReilly @MPishvaian @mkatzmd @DenboJw @TheNotoriousHPB…
@SyedAAhmad5 @Aiims1742 @CathyEngMD @agrothey @pashtoonkasi @EileenMOReilly @MPishvaian @mkatzmd @DenboJw @TheNotoriousHPB @DrJashDatta @TsengJennifer @sepideh_gholami @GIcancerDoc @Shrikhande_SV @ShaalanBeg @SWexner https://t.co/CFHsyTX3q5 1st trial to provide level 1 evidence of survival benefit from immunotherapy in melanoma. Although PD1 blockers have been more efficacious, this study of anti-CTLA-4 led to a transformation in the practice of oncology. @WalterUrba @ODayMD @wolchokj
RT @TheNotoriousHPB: @pashtoonkasi @SyedAAhmad5 @Aiims1742 @CathyEngMD @agrothey @EileenMOReilly @MPishvaian @mkatzmd @DenboJw @DrJashDatta…
@pashtoonkasi @SyedAAhmad5 @Aiims1742 @CathyEngMD @agrothey @EileenMOReilly @MPishvaian @mkatzmd @DenboJw @DrJashDatta @TsengJennifer @sepideh_gholami @GIcancerDoc @Shrikhande_SV @ShaalanBeg @SWexner @ScienceMagazine But this one opened the doors to IT in solid tumors. When it’s all said and done, it will be all about immunotherapy. https://t.co/1rxKmQGzoj
RT @BernardAFox: #ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of frie…
RT @BernardAFox: #ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of frie…
RT @BernardAFox: #ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of frie…
RT @BernardAFox: #ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of frie…
RT @BernardAFox: #ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of frie…
#ASCO2010 opened the #Cancer #Immunotherapy decade! #melanoma talk by @ODayMD @JohnWayneCI & @NEJM paper with lots of friends 1st au Dr Stephen Hodi @DanaFarber & Sr au @WalterUrba @ChilesResearch https://t.co/ytNvZYEqEh lead to 2018 @NobelPrize @sitcancer @BMS_ImmunOnc_US https://t.co/gjjVlksq6Z